LONDON: Global pharmaceutical giant AstraZeneca has announced an ambitious plan to invest $50 billion in the United States by 2030, marking the company’s largest-ever single-country commitment. The move aims to scale up drug manufacturing, create jobs, and enhance domestic pharmaceutical capabilities across the US.
AstraZeneca confirmed that the investment will support the development of a new state-of-the-art drug substance facility in Virginia, which will become the company’s largest manufacturing site globally. The facility will focus on producing next-generation weight management and cardiovascular treatments including oral GLP‑1s, baxdrostat, and PCSK9 small molecules, using advanced AI and data analytics.
The company’s expansion plan will also fund research and manufacturing upgrades across Maryland, Massachusetts, Indiana, California, and Texas. These include expanded R&D hubs, cell therapy centres, and upgraded production lines to ensure supply chain resilience and innovation capacity.
AstraZeneca’s CEO Pascal Soriot highlighted that this $50 billion US investment aligns with the company’s strategic growth vision to reach $80 billion in global revenue by 2030, with the US accounting for half. He added that the Virginia site reflects AstraZeneca’s commitment to cutting-edge technology and sustainable healthcare solutions.
Government leaders welcomed the investment, with Virginia Governor Glenn Youngkin noting it would deliver high-quality skilled jobs and reinforce the US as a leader in global medicine production. US Commerce Secretary Howard Lutnick praised the move as vital to national pharmaceutical independence.
This major US expansion by AstraZeneca demonstrates the increasing focus on domestic production amid shifting global trade dynamics and positions the UK-based company as a key player in shaping the future of medicine.
